cancer-research-structural-biochemistry-2019-tracks

Page 22

Volume 3

August 5-6, 2019 | Singapore

CANCER RESEARCH AND PHARMACOLOGY

STRUCTURAL BIOCHEMISTRY, STEM CELLS AND MOLECULAR BIOLOGY

International Conference on

International Congress on

Cancer Research 2019 & Structural Biochemistry 2019

August 5-6, 2019

Journal of Cancer and Metastasis Research

Clin Psychol Cog Sci, Volume 3

TargetingAxl/EZH/Sox2 for glioblastoma multiform by novel biodegradable interstitial

delivery system

The IND of Cerebraca® wafer has been approved by FDA for phase I/IIa. This clinical

trial has been conducted at Tzu-Chi University Hospital in, Hualien, Taiwan

Horng-Jyh Harn

Buddhist Tzu Chi Medical Foundation, Taiwan

argeting Cerebraca ® wafer, also known as BP/polymer

wafer, is a biodegradable wafer for interstitial implantation

comprises butylidenephthalide (BP; the active moiety; EF-001) and

Carboxyphenoxypropane-Sebacic Acid Copolymer (CPPSA).

The anti-glioblastoma pharmacology effect of BPwas identified in yellowish

brown root of the plant Angelica sinensis, a well-known Chinese medicine.

The antitumor effects of A. sinensis extracts were firstly evaluated in several

human cancer cell lines, including a human glioblastoma multiform (GBM)

cell line. These antitumor activity was suggested resulting from the effects

of BP in suppression of telomerase level (Lin et al. 2011), up-regulation of nuclear receptor Nur77 (an apoptosis mediator) (Lin et al.,

2008), reducing glioma migration and invasion mediated by Axl-1 tyrosine receptor (Yen et al., Oncogene, 2016) and tumor stem cell

Sox-2 genes (unpublished data). More importantly, BP further showed the effects on reversing Temozolomide (TMZ) resistance by

suppressing O6-methylguanine-DNA-methyltransferase (MGMT) mRNA and protein expression (Harn et al., 2013). Taken together,

the targeting genes of BP are Axl/EZH2/SOX2, telomerase, DNA repair gene MGMT.

In order to overcome the limitation of blood-brain barrier, a local interstitial delivery system which BP incorporated into a

biodegradable polyanhydride material CPPSA, namely, the BP/polymer wafer was applied. This novelty contributes the efficient

effects on survival (2.44 time prolonged more than Gliadel® wafers).

At present, we have completed the project in a chemical manufacturing and control, preclinical efficacy and preclinical safety

assessment and other tests. The IND of Cerebraca® wafer has been approved by FDA for phase I/IIa. This clinical trial will be

conducted at Tzu-Chi University Hospital in, Hualien, Taiwan.

So far, we have finished cohort II six patients study. No safety issue is found. The first patient has been extending eleven months.

Biography

Horng-Jyh Harn, M.D. Ph.D current serves at the department of pathology at Tzu-Chi University as a professor and surgical pathologist

and associate vice president, Bioinnovation Center, Tzu Chi foundation. He also owns PhD degree at pathology department of Duke

University, Durham, USA (1987-1991). Previously, he was a professor in the Department of Pathology at the National Defense Medical

Center, Taipei, Taiwan (1997-2002). He received his surgical pathology training at Tri-Service General Hospital, Taipei, Taiwan. He was

appointed as a Director of Molecular Medicine, Tzu-Chi Buddhist General Hospital, Hualien, Taiwan; Chairman of Pathology, China

medical university, Taichung, Taiwan. He is the author of over 120 original research articles and has been granted over 30 patents, both

nationally and internationally. His main research interesting fields are molecular biology, tumor oncology, stem cell research and new

drug development against neurological disease.